Kaira has led the development and optimization of Turbohaler inhalers by integrating advanced computational modeling and automated testing techniques.
The goal is to enhance drug delivery efficiency while ensuring compliance with international safety and efficacy standards.
The Turbohaler is a dry powder inhaler designed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
It enables patients to inhale medication in finely dispersed particles, improving drug deposition in the lungs and optimizing therapeutic outcomes.
The device operates through a breath-actuated mechanism, eliminating the need for external propellants.
As the patient inhales, air passes through the inhaler, dispersing the powdered medication into an aerosolized form that can reach deep into the respiratory system.
Its design minimizes resistance, ensuring efficient drug delivery while improving patient adherence to treatment.
Kaira has developed a high-precision simulation framework for modeling aerodynamic flows within the Turbohaler, optimizing drug dispersion.
Additionally, a hardware-in-the-loop (HIL) testing system was implemented for real-time validation of inhaler performance under various conditions.
Compliance validation according to ISO 20072 was also conducted, ensuring that the device meets stringent safety and efficacy regulations.